Literature DB >> 15545086

Sequence specificity of alternating hydroyprolyl/phosphono peptide nucleic acids against zebrafish embryo mRNAs.

E Wickstrom1, M Choob, K A Urtishak, X Tian, N Sternheim, S Talbot, J Archdeacon, V A Efimov, S A Farber.   

Abstract

Morpholino phosphorodiamidate (MO) DNA mimics display excellent water solubility and hybridization properties toward DNA and RNA, and have been utilized in the model vertebrate zebrafish (Danio rerio) for genome-wide, sequence-based, reverse genetic screens during embryonic development. Peptide nucleic acids (PNAs) exhibit excellent mismatch discrimination, nuclease resistance, and protease resistance, but low solubility. Negatively charged DNA mimics composed of alternating residues of trans-4-hydroxy-L-proline peptide nucleic acid monomers and phosphono peptide nucleic acid monomers (HypNA-pPNA) combine all of the positive features of both MOs and PNAs. Thus, we evaluated PNA oligomers and HypNA-pPNA oligomers as an alternative to MOs for oligonucleotide inhibition of gene expression in zebrafish embryos. We observed that HypNA-pPNA 18-mers displayed comparable potency to MO 25-mers as knockdown agents against chordin, notail and uroD, with greater mismatch stringency. Furthermore, we observed that a specific HypNA-pPNA 18-mer elicited the dharma (bozozok)(-/-) phenotype in zebrafish embryos, which MO 25-mers do not. These observations validate HypNA-pPNAs as an alternative to MO oligomers for reverse genetic studies. The stronger hybridization and greater specificity of HypNA-pPNAs enable knockdown of mRNAs unaffected by MO oligomers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545086     DOI: 10.1080/10611860412331285242

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  8 in total

Review 1.  DNA and RNA derivatives to optimize distribution and delivery.

Authors:  Eric Wickstrom
Journal:  Adv Drug Deliv Rev       Date:  2015-04-22       Impact factor: 15.470

Review 2.  Zebrafish: a model system for the study of eye genetics.

Authors:  James M Fadool; John E Dowling
Journal:  Prog Retin Eye Res       Date:  2007-09-07       Impact factor: 21.198

3.  Coordinate control of cell cycle regulatory genes in zebrafish development tested by cyclin D1 knockdown with morpholino phosphorodiamidates and hydroxyprolyl-phosphono peptide nucleic acids.

Authors:  Kevin T Duffy; Mary Frances McAleer; William R Davidson; Laszlo Kari; Csaba Kari; Chang-Gong Liu; Steven A Farber; Keith C Cheng; Jason R Mest; Eric Wickstrom; Adam P Dicker; Ulrich Rodeck
Journal:  Nucleic Acids Res       Date:  2005-09-02       Impact factor: 16.971

4.  Hydroxyproline-based DNA mimics provide an efficient gene silencing in vitro and in vivo.

Authors:  Vladimir A Efimov; Klara R Birikh; Dmitri B Staroverov; Sergei A Lukyanov; Maria B Tereshina; Andrey G Zaraisky; Oksana G Chakhmakhcheva
Journal:  Nucleic Acids Res       Date:  2006-05-02       Impact factor: 16.971

5.  Subnanomolar antisense activity of phosphonate-peptide nucleic acid (PNA) conjugates delivered by cationic lipids to HeLa cells.

Authors:  Takehiko Shiraishi; Ramin Hamzavi; Peter E Nielsen
Journal:  Nucleic Acids Res       Date:  2008-07-02       Impact factor: 16.971

6.  In search of visible-light photoresponsive peptide nucleic acids (PNAs) for reversible control of DNA hybridization.

Authors:  Lei Zhang; Greta Linden; Olalla Vázquez
Journal:  Beilstein J Org Chem       Date:  2019-10-22       Impact factor: 2.883

7.  Side chain modified peptide nucleic acids (PNA) for knock-down of six3 in medaka embryos.

Authors:  Sebastian Dorn; Narges Aghaallaei; Gerlinde Jung; Baubak Bajoghli; Birgit Werner; Holger Bock; Thomas Lindhorst; Thomas Czerny
Journal:  BMC Biotechnol       Date:  2012-08-17       Impact factor: 2.563

Review 8.  "Zebrafishing" for novel genes relevant to the glomerular filtration barrier.

Authors:  Nils Hanke; Lynne Staggs; Patricia Schroder; Jennifer Litteral; Susanne Fleig; Jessica Kaufeld; Cornelius Pauli; Hermann Haller; Mario Schiffer
Journal:  Biomed Res Int       Date:  2013-09-11       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.